Claims
- 1. A compound of Formula I its prodrug forms or pharmaceutically acceptable salts thereof, whereinR1 represents OH; R2 represents phenyl or nitrophenyl; R3 represents H; R4 represents (CH2)0-2-tetrazolyl or (CH2)0-2-triazolyl; R5 represents H; R6 represents H; R7 represents amino, amidino or guanidino; R8 represents halogen; and R9 represents H.
- 2. A compound of claim 1 selected from6-Chloro-2-[2-hydroxy-5-(1H-tetrazol-5-yl)-biphenyl-3-yl]-1H-indole-5-carboxamidine; 6-Fluoro-2-[2-hydroxy-5-(1H-tetrazol-5-yl)-biphenyl-3-yl]-1H-indole-5-carboxamidine; 6-Fluoro-2-[2-hydroxy-3′-nitro-5-(1H-tetrazol-5-yl)-biphenyl-3-yl]-1H-indole-5-carboxamidine; 6-Chloro-2-[2-hydroxy-3′-nitro-5-(1H-tetrazol-5-yl)-biphenyl-3-yl]-1H-indole-5-carboxamidine; 6-Chloro-2-[2-hydroxy-3′-nitro-5-(3H-[1,2,3]triazol-4-yl)-biphenyl-3-yl]-1H-indole-5-carboxamidine; 6-Chloro-2-[2-hydroxy-5-(3H-[1,2,3]triazol-4-yl)-biphenyl-3-yl]-1H-indole-5-carboxamidine; 6-Fluoro-2-[2-hydroxy-5-(3H-[1,2,3]triazol-4-yl)-biphenyl-3-yl]-1H-indole-5-carboxamidine; and 6-Fluoro-2-[2-hydroxy-3′-nitro-5-(3H-[1,2,3]triazol-4-yl)-biphenyl-3-yl]-1H-indole-5-carboxamidine.
- 3. A compound of Formula I its prodrug form or pharmaceutically acceptable salt thereof, whereinR1 represents OH; R2 represents phenyl; R3 represents H; R4 represents tetrazolyl or triazolyl; R5 represents H; R6 represents H; R7 represents amidino; R8 represents halogen; and R9 represents H.
- 4. A compound of Formula I: whereinR1 represents OH; R2 represents nitrophenyl; R3 represents H; R4 represents tetrazolyl or triazolyl; R5 represents H; R6 represents H; R7 represents amidino; R8 represents halogen; and R9 represents H.
- 5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
- 6. A method for treating a cancer related disorder, comprising administering to a patient/mammal in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
- 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.
- 8. A method for treating a cancer related disorder, comprising administering to a patient/mammal in need thereof a therapeutically effective amount of a compound of claim 3 or a pharmaceutically acceptable salt thereof.
- 9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4, or a pharmaceutically acceptable salt thereof.
- 10. A method for treating a cancer related disorder, comprising administering to a patient/mammal in need thereof a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt thereof.
Parent Case Info
This application is based on and claims priority from U.S. Provisional Application S.No. 60/224,712 filed on Aug. 11, 2000.
Foreign Referenced Citations (2)
Number |
Date |
Country |
WO 99 41231 |
Aug 1999 |
WO |
WO 0035886 |
Jun 2000 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/224712 |
Aug 2000 |
US |